Validating the SPUR Medication Adherence Tool in Type 2 Diabetes

  • Research type

    Research Study

  • Full title

    A feasibility study to validate the SPUR questionnaire as a model to measure adherence and the impact of readmission in Type 2 Diabetes

  • IRAS ID

    270768

  • Contact name

    Reem Kayyali

  • Contact email

    r.kayyali@kingston.ac.uk

  • Sponsor organisation

    Kingston Hospital

  • Duration of Study in the UK

    1 years, 0 months, 1 days

  • Research summary

    Approximately half of all patients suffering from a long-term condition struggle to take their medicines correctly. Often issues such as the side-effects and number of medicines can pose as challenges to continuation of treatment for patients. Despite a wealth of research on the topic, we still do not fully understand what factors contribute to this problem. This project aims to use a questionnaire that has been developed by Observia, an e-health solution organisation, to investigate the obstacles faced by patients as well as their behaviour when it comes to taking medicines. More specifically, the project will focus on patients that are taking medicines for Type 2 Diabetes. Patients with uncontrolled diabetes are at a high risk of complications such as kidney disease and heart attacks, which means an increased cost to the health services supporting them. To better support patients and their healthcare providers, this questionnaire is a new approach to looking at how well people take their medicines. Therefore, the study will compare the tool to other similar questionnaires to ensure that the tool is reliable. We will be working with patients in the hospital to complete the questionnaire and to provide feedback about how they take their medicines. Additionally, we would like to understand if patients who struggle to take their medicines are more likely to access hospital services. Therefore, we aim to find out from patients more information about their previous hospital visits, and any potential future visits they might have while taking part in the study over the course of 6 months. Once we have confirmed that our questionnaire is reliable, we will be looking at ways in which we can use the information we have collected to help improve patient care and diabetes control, which we hope can reduce complications and costs to healthcare providers.

  • REC name

    North West - Greater Manchester East Research Ethics Committee

  • REC reference

    19/NW/0685

  • Date of REC Opinion

    20 Dec 2019

  • REC opinion

    Further Information Favourable Opinion